In the future, this information will be applied toward modulating the outcome of therapies designed to overcome diseases involving metals.
In the future, this information will be also organized by science category and instrument, such as "point source, ACIS-S, no grating".
In the future, this information will be captured automatically from the health care provider's electronic medical records system.
In the future, when such information will be available, it can be used for improving the performances of our predictor.
Already today, and much more so in the future, DNA sequence information will be used to establish and confirm diagnoses, to help determine treatment, and to prevent disease through presymptomatic identification of genetic risk.
We can foresee that in the near future more precise information will be available allowing the assessment of a sex-specific exposure to disease risk on the basis of presence of a given either a single or a combination of SNPs.
COBALT requires the user to define the length of time that is being studied, requiring the current year, a 'base year' with which to compare data, and then up to five specified dates in the future at which all information will be calculated.
Development of additional tools like functional annotation networks based on expression information will be future steps towards a systematic biological analysis of expression profiles.
Consequently, for occasionally used drugs, neither of the registers is more advantageous than the other as the only source of information for drug exposure, and for future studies, presumably the combined information will be the best estimate.
The expected value of perfect and partial information will be estimated to inform future data collection.
